|
|
|
| Comparison of Efficacy and Safety of Rivaroxaban and Low-molecular-weight Heparin Calcium in the Prevention of Deep Vein Thrombosis in Tumor Patients |
| LI Bo, CHEN Lixia, RAO Minchao |
| First-author's address: Shangrao People's Hospital, Jiangxi Province, Shangrao 334000, China |
|
|
|
|
Abstract Objective: To compare the safety and efficacy of Rivaroxaban and Low-molecular-weight Heparin Calcium in preventing deep vein thrombosis in tumor patients receiving chemotherapy. Method: A total of 80 hospitalized patients diagnosed with malignant tumor and receiving chemotherapy admitted to Shangrao People's Hospital from January 2018 to September 2022 were selected, they were divided into experimental group (n=39) and control group (n=41) by random number table method. The experimental group was given Rivaroxaban to prevent deep vein thrombosis, and the control group was given Low-molecular-weight Heparin Calcium to prevent thrombosis. The coagulation indexes [prothrombin time (PT), thrombin time (TT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (D-D)] before and after medication were compared between the two groups, the blood clots and bleeding events in the two groups were observed during treatment, and the test results were statistically analyzed. Result: There were no significant differences in the coagulation indexes before and after treatment between the two groups (P>0.05). After treatment, there were no significant differences in PT, TT, APTT and FIB between the two groups (P>0.05). The D-D in the experimental group was (3.32±1.10) mg/L after treatment, which was lower than (6.00±1.54) mg/L before treatment, the D-D in the control group was (3.66±1.01) mg/L, which was lower than (5.84±1.73) mg/L before treatment, the differences were statistically significant (P<0.05). No thrombotic events occurred in both two groups during treatment, and 1 patient in the experimental group appeared a less hematochezia, the incidence of hemorrhagic events was 2.6% (1/39) in the experimental group and 0 in the control group, there was no significant difference between the two groups (P>0.05). Conclusion: Rivaroxaban compared with Low-molecular-weight Heparin Calcium, there are no significant difference in the efficacy and safety of preventing deep vein thrombosis in malignant tumor patients receiving chemotherapy, and no significant effect on PT, TT, APTT and FIB, all of which could significantly reduce D-D levels.
|
|
Received: 23 February 2023
|
|
|
|
|
|
|
